Περίληψη:
Background and objective: The fibrinolytic regulator tetranectin (TN),
in association with the circulating intercellular adhesive molecule-1
(clCAM-1) and interleukin-10 (IL-10), may be involved in the metastatic
cascade of B-chronic lymphocytic leukemia (B-CLL). Our aim was to
investigate the potential usefulness of these molecules as prognostic
markers in B-CLL.
Design and methods: Therefore, TN, clCAM-1, and IL-10 were assessed
(ELISA) in the serum of 53 B-CLL patients, classified in Binet A, B, and
C stages in comparison with those in 45 healthy subjects (HS).
Results: TN was significantly lower in B-CLL patients than in HS (9.63
[8.75-11.51] mg/L, 13.75 [12.56-14.64] ng/mL, respectively. p <
10(-5)), being lower (p = 0.05) in B and C stage patients (subgroup B+C)
than in A stage ones (subgroup A). clCAM-1 levels were significantly
higher in B-CLL patients than in HS (475.86 [355.86-593.79] ng/mL vs.
225.62 [118.49-312.83] ng/mL, respectively, p = 10-5) with a tendency
for higher levels in subgroup B+C than in subgroup A. A significant
correlation of clCAM-1 with lactate dehydrogenase (LDH) (r(s) = 0.532, p
= 0.049), and a significant increase in clCAM-1 in B-CLL with diffuse
bone marrow infiltration (BMI) compared to that in B-CLL with nondiffuse
BMI (624.48 [557.24-726.55] ng/mL vs. 480.34 [368.96-590.34] ng/mL,
respectively, p = 0.0172) were found. A significant negative correlation
between TN and clCAM-1 (r(s) = -0.5017, p = 0.0001) was observed. IL-10
was detected in all B-CLL patients and in no HS (7.37 [5.30-10.55]
pg/mL), being higher (p = 0.0153) in C than in A stage patients. A
significant correlation of IL-10 with TN and clCAM-1 in subgroup B+C
(r(s) = -0.659 [p = 0.014] and r(s) = 0.679 [p = 0.011],
respectively) was found.
Conclusions: The abovementioned findings and good performance
characteristics of TN and clCAM-1 in B-CLL suggest the potential
usefulness of these adhesive/recognition molecules as prognostic markers
in B-CLL. The implication of these molecules along with IL-10 in the
disease process deserves further study. Copyright (C) 1999 The Canadian
Society of Clinical Chemists.
Συγγραφείς:
Kamper, EF
Papaphilis, AD
Angelopoulou, MK
Kopeikina, LT and
Siakantaris, MP
Pangalis, GA
Stavridis, JC
